-
Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer
03 Jun 2024 20:33 GMT
… benefit patients with EGFR-mutated lung cancer given as a single agent … progress in the treatment of lung cancer over the past 2 … of therapies for patients with lung cancer,” he said. “Now, my … 5.5 months after completing chemoradiation, 90% of the patients …
-
At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer
02 Jun 2024 19:20 GMT
… for non-small cell lung cancer (NSCLC) positive for … non-small cell lung cancer following definitive chemoradiation, and EGFR mutation … extensive-stage small cell lung cancer. The latest results are … are different types of lung cancer. Next steps include …
-
Posttreatment Imfinzi Sets New Standard for Small Cell Lung Cancer
02 Jun 2024 14:47 GMT
… lung cancer (LS-SCLC).
When given as a consolidation treatment after chemoradiation … 3 non–small cell lung cancer, and that demonstrated … months. Similar to other lung cancers, and you’ve heard … related to personalization of lung cancer treatment for patients, …
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
02 Jun 2024 12:23 GMT
… .
Notes
Small cell lung cancer
Lung cancer is the leading cause … to its indications in lung cancers, IMFINZI is approved … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed … chemoradiation for patients with limited stage small cell lung cancer. …
-
Consolidation Durvalumab After Chemoradiation Reduces Mortality Risk by 27% in Limited-Stage SCLC
02 Jun 2024 12:28 GMT
… ) as consolidation treatment after concurrent chemoradiation significantly improved survival compared with … in months. Similar to other lung cancers, and you’ve heard about … advances related to personalization of lung cancer treatment for patients, we now …
-
Osimertinib May Change Standard of Care for Stage III EGFR+ NSCLC After Definitive Chemoradiation
02 Jun 2024 12:28 GMT
… , stage III non–small cell lung cancer (NSCLC) with an EGFR mutation … ], locally advanced NSCLC following definitive chemoradiation. EGFR mutation testing should be … following chemoradiation in patients with stage III unresectable non-small cell lung cancer …
-
Candel Reports Upbeat Data From Lung Cancer Study
24 May 2024 19:51 GMT
… /IV non-small cell lung cancer (NSCLC) who are non-responsive … plus valacyclovir, together with SoC chemoradiation, followed by resection for borderline …
-
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
22 May 2024 11:18 GMT
… EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy ( … across earlier-stage lung cancer settings
Several presentations … Presentation details (CDT)
Lung Cancers
Ramalingam, SS
Osimertinib ( … NSCLC following definitive chemoradiation within 42 days …
-
ASCO Meeting preview – A focus on Lung Cancer in Chicago and new treatments
20 May 2024 10:16 GMT
… cell lung cancer who have been treated with pembrolizumab plus concurrent chemoradiation therapy … potential for significant improvements in lung cancer outcomes in recent years.
… in lung cancer,” Prof Naidoo told the meeting.
“Every patient with lung cancer …
-
Dr Liu Previews ASCO 2024 Lung Cancer Data
18 May 2024 00:37 GMT
… consolidation osimertinib (Tagrisso) following chemoradiation in patients with unresectable, … free survival following chemoradiation vs placebo after chemoradiation. This study … conference for advancements in lung cancer management, with numerous studies …